COVID-19

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Robert P....

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will...

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will...

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will...

Penn Medicine, Children’s Hospital of Philadelphia team awarded Breakthrough Prize for developing gene therapy for inherited blindness

LOS ANGELES, April 18, 2026 /PRNewswire/ -- Their discovery started with a group of blind dogs living at a vet school....

Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study...

Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes

Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems...

error: Content is protected !!